Astria Therapeutics Inc Stock Price, News & Analysis

Astria Therapeutics (NASDAQ:ATXS) is set to present two posters at the Bradykinin Symposium in Berlin on September 6, 2024. The presentations focus on navenibart (STAR-0215), a potential therapy for Hereditary Angioedema (HAE).

Dr. Chris Morabito, Chief Medical Officer, will present on the ALPHA-SOLAR trial, a long-term open-label study of navenibart in HAE patients. Kusumam Joseph, Senior Director of Medical Affairs, will share updated results from the Phase 1a trial of navenibart.

These presentations highlight Astria's progress in developing treatments for allergic and immunologic diseases, particularly HAE. The symposium provides a platform for Astria to showcase its advancements in bradykinin-related therapies to the scientific community.

Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company specializing in allergic and immunologic diseases, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 5th in New York City.

This conference provides Astria Therapeutics with a platform to showcase its progress in developing life-changing therapies and potentially connect with investors and industry professionals. The company's attendance at such a prestigious healthcare conference highlights its commitment to advancing its research and development efforts in the field of allergic and immunologic diseases.

Astria Therapeutics (NASDAQ:ATXS) reported Q2 2024 financial results and provided a corporate update. Key highlights:

1. Navenibart (STAR-0215) for HAE treatment is on track for Phase 3 initiation in Q1 2025.
2. Preclinical results support STAR-0310 as a potential best-in-class OX40 inhibitor.
3. Cash position of $354.7 million as of June 30, 2024, expected to fund operations into mid-2027.
4. Q2 2024 net loss of $24.2 million ($0.43 per share) compared to $12.6 million ($0.45 per share) in Q2 2023.
5. R&D expenses increased to $20.7 million in Q2 2024 from $9.1 million in Q2 2023.

Astria Therapeutics (NASDAQ:ATXS) has chosen Ypsomed as its partner to develop an autoinjector for STAR-0215, a therapy for Hereditary Angioedema (HAE). The collaboration aims to support Astria's goal of offering patients a choice between infrequent three- and six-month administration options. Astria plans to launch STAR-0215 with both the Ypsomed YpsoMate autoinjector and a pre-filled syringe, pending regulatory approval. The autoinjector is considered ideal for STAR-0215 due to its ease of use, needle shielding feature, and quick injection with low risk of pain. This partnership aligns with Astria's vision of providing effective HAE attack protection while minimizing treatment burden.

Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company specializing in allergic and immunological diseases, has announced its participation in the 2024 Wedbush PacGrow Healthcare Conference in New York, NY. The company's CEO, Jill C. Milne, Ph.D., will be part of a panel discussion titled 'HAE Ya! The Changing Face of the HAE Therapeutic Landscape' on Wednesday, August 14 at 2:30pm ET.

This panel will focus on hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling in various parts of the body. Astria's participation in this conference highlights its commitment to advancing therapies for HAE and other immunological conditions, potentially impacting its stock performance and investor interest in the biopharmaceutical sector.

Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company focused on allergic and immunological diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options, totaling 29,150 shares of common stock, were awarded on August 1, 2024, with an exercise price of $11.19 per share, matching the closing price on the grant date.

These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.

Astria Therapeutics (Nasdaq: ATXS) announced the grant of stock options for 123,500 shares of its common stock on July 1, 2024, under its 2022 Inducement Stock Incentive Plan.

This grant, aimed at three new employees, aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for their employment.

Each option has an exercise price of $9.25, equal to the closing price on the grant date, and will vest over four years.

25% of the shares will vest after the first year of employment, with the remainder vesting monthly over the next three years, contingent on continued employment.

Astria Therapeutics announced on June 3, 2024, that it has granted stock options to purchase 40,000 shares of common stock under its 2022 Inducement Stock Incentive Plan. These options were provided as an inducement to a new employee, with the exercise price set at $9.16, matching the closing price of the stock on the grant date. The vesting schedule spans four years: 25% on the first anniversary of the employee's start date and the remaining shares vesting monthly over the next 36 months. The grants comply with Nasdaq Listing Rule 5635(c)(4).

Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in therapies for allergic and immunological conditions, announced that CEO Jill C. Milne, Ph.D., will participate in a fireside chat at the Jefferies Healthcare Conference. The event is scheduled for June 6th at 10:00am ET in New York, NY. A webcast of the presentation will be available live and as an archived replay for 30 days on the company's investor relations website.